Insight Pharma Reports Announces Liquid Biopsy Report

NEEDHAM, Mass. - March 12, 2015 - PRLog -- Cambridge Healthtech Institute’s Insight Pharma Reports announces the Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management, authored by Kenneth Rubenstein, Ph.D.

Just published, this report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.

Report Highlights Include:

- Market dynamics including market size estimates along with five-year projections by application segment, the competitive environment and deal activity.
- Commercial aspects of liquid biopsy with profiles of over 30 companies.
- Survey results from117 industry experts conducted by Insight Pharma Reports exclusively for this report.

Exclusive transcripts from extended interviews with:

- Nicholas Dracopoli, Ph.D., Vice President Oncology Translational Research, Janssen Pharmaceuticals
- Paul Dempsey, Ph.D., Chief Scientific Officer, Cynvenio Biosystems
- Johan Skog, Ph.D., CSO and Founding Scientist, Exosome Diagnostics
- Lidia Sambucetti, PhD, Sr. Director of Cancer Biology, and Ted Ira, Director of Sales, SRI Biosciences Div.
- Harry Glorikian, Life Sciences Consultant

For more information and to purchase this Insight Pharma Report, visit: www.InsightPharmaReports.com

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  www.InsightPharmaReports.com